THE OCULAR effects of a new anticholinesterase chemical, tetraethyl pyrophosphate, have been investigated in several subjects with normal eyes and in several patients with glaucomatous eyes. Although the number of observations is small, the information obtained appears to be adequate for a qualitative characterization of the actions of this compound. A more quantitative experimental comparison of tetraethyl pyrophosphate with physostigmine and di-isopropyl fluorophosphate (DFP) and a clinical comparison with di-isopropyl fluorophosphate in glaucomatous and in atropinized eyes are to be reported subsequently.1
Tetraethyl pyrophosphate is a colorless, water-soluble and lipidsoluble, hygroscopic liquid of low volatility. It is the principal active ingredient of a more complex substance, commercial hexaethyl tetraphosphate (tri-diethyl phosphophosphate), which, because of strong nicotine-like action, was used in Germany during the war as an insecticide, substituting for natural nicotine, under the name of ``bladan.''2 Tetraethyl pyrophosphate is being used increasingly in this country for the same
GRANT WM. MIOTIC AND ANTIGLAUCOMATOUS ACTIVITY OF TETRAETHYL PYROPHOSPHATE IN HUMAN EYES. Arch Ophthalmol. 1948;39(5):579–586. doi:10.1001/archopht.1948.00900020588002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: